T7-Functionalized Cationic Peptide as a Nanovehicle for Co-delivering Paclitaxel and siR-MeCP2 (2021)
Sequence: T7: HAIYPRH; SHRss: Stearyl-HHHCRRRRRC (disulfide-crosslinked)
| Experiment Id | EXP000237 |
|---|---|
| Paper | T7-Functionalized Cationic Peptide as a Nanovehicle for Co-delivering Paclitaxel and siR-MeCP2 |
| Peptide | T7-PEG-SHRss |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | N/P = 10 |
| Rna Concentration | ~2 mg/kg (in vivo); 50 nM (in vitro) |
| Mixing Ratio | N/P = 10 |
| Formulation Format | targeted peptide nanoparticle (CTNP) |
| Formulation Components | T7-PEG-SHRss + siRNA ± paclitaxel |
| Size Nm | 140.00 |
| Zeta Mv | 17.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | LNCaP; PC3 |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | Significant MeCP2 protein downregulation |
| Output Units | |
| Output Notes | T7 enhances uptake; SHRss enables endosomal escape via histidine-rich segments |
| Toxicity Notes | Low cytotoxicity without PTX |
| Curation Notes |